GlassScriptPhysician profile
Alfred S Barritt
NPI 1154395879
$210,450.07
in general payments reported to CMS, 2019-2025
25 companies · $128K in 2025
The $128K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $11K · 2022: $15K · 2023: $1,878 · 2024: $41K · 2025: $128K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Consulting Fee: $48K · Travel and Lodging: $26K · Food and Beverage: $5,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,520.75 |
| Consulting Fee | $48,290.00 |
| Travel and Lodging | $26,200.37 |
| Food and Beverage | $5,244.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $98,512.70 | 2024-2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41,043.83 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $16,055.58 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $13,555.14 | 2019-2020 | |
| Boehringer Ingelheim International Gmbh | $11,935.93 | 2025 | |
| Dova Pharmaceuticals | $8,400.10 | 2019 | |
| Mirum Pharmaceuticals, INC. | $6,176.53 | 2024 | Livmarli |
| Gilead Sciences, INC. | $4,768.89 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $3,473.02 | 2024-2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,355.01 | 2019-2023 | Xifaxan |
| Sarepta Therapeutics, INC. | $1,710.00 | 2022 | |
| Celgene Corporation | $835.72 | 2019 | |
| Mallinckrodt Hospital Products INC. | $249.47 | 2023-2024 | Terlivaz |
| Abbvie INC. | $119.99 | 2019-2022 | |
| Novo Nordisk INC | $104.00 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steris Corporation | $101.16 | 2022 | |
| Ionis Pharmaceuticals, INC. | $36.77 | 2025 | |
| Pfizer INC. | $16.23 | 2022 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Barritt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.